Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: Study 8541 from the cancer and leukemia group B

Journal of Clinical Oncology

Volumn 26, Issue 14, 2008, Pages 2364-2372

  DiGiovanna, Michael P ^a   Stern, David F ^a   Edgerton, Susan ^a   Broadwater, Gloria ^a   Dressler, Lynn G ^a   Budman, Daniel R ^a   Henderson, I Craig ^a   Norton, Larry ^a   Liu, Edison T ^a   Muss, Hyman B ^a   Berry, Donald A ^a   Hayes, Daniel F ^a   Thor, Ann D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PARAFFIN; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER PATIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STAINING; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENETICS; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME ACTIVATION; FEMALE; FLUOROURACIL; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; NEOPLASM STAGING; PHOSPHORYLATION; RECEPTOR, ERBB-2;

EID: 44249089760     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.6580     Document Type: Article

References (33)

1. DiGiovanna MP: Clinical significance of HER-2/neu overexpression: Part I, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology: Principles and Practice of Oncology Updates (ed 9). Cedar Knolls, NJ, Lippincott Williams & Wilkins, 1999
2. DiGiovanna MP: Clinical significance of HER-2/neu overexpression: Part II, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology: Principles and Practice of Oncology Updates (ed 10). Cedar Knolls, Lippincott Williams & Wilkins, 1999
3. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334-2356, 2001
4. Isaacs C, Stearns V, Hayes DF: New prognostic factors for breast cancer recurrence. Semin Oncol 28:53-67, 2001
5. neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 55:1946-1955, 1995
6. DiGiovanna MP, Roussel RR, Stern DF: Production of antibodies that recognize specific tyrosine-phosphorylated peptides, in Ausubel FM, Brent R, Kingston RE, et al (eds): Current Protocols in Molecular Biology. New York, John Wiley & Sons, Inc, 1996, pp 18.6.1-18.6.19
7. DiGiovanna MP, Carter D, Flynn SD, et al: Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer 74:802-806, 1996
8. Thor AD, Liu S, Edgerton S, et al: Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and corrrelation with outcome in breast cancer. J Clin Oncol 18:3230-3239, 2000
9. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
10. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1998
11. Muss HB, Thor AD, Berry DA, et al: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
12. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998
13. Dressler LG, Berry DA, Broadwater G, et al: Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-4297, 2005
14. Cox DR: Regression models and life-tables (with discussion). Journal Royal Statistical Society, Series B 34:187-220, 1972
15. Keith WN, Douglas F, Wishart GC, et al: Co-amplification of erbB2, topoisomerase II a and retinoic acid receptor a genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer 29A:1469-1475, 1993
16. Jarvinen TAH, Tanner M, Barlund M, et al: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150, 1999
17. Jarvinen TAH, Tanner M, Rantanen V, et al: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. American J Pathol 156:839-847, 2000
18. Järvinen TAH, Liu ET: Her-2/neu and topoisomerase IIa in breast cancer. Breast Cancer Res Trt 78:299-311, 2003
19. Harris LN, Yang L, Tang C, et al: Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin -2. Clinical Cancer Res 4:1005-1012, 1998
20. Harris LN, Yang L, Liotcheva V, et al: Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clinical Cancer Res 7:1497-1504, 2001
21. Paik S, Bryant J, Park C, et al: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
22. Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998, 2000
23. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006
24. Di Leo A, Gancberg D, Larsimont D, et al: HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clinical Cancer Res 8:1107-1116, 2002
25. Tanner M, Isola J, Wiklund T, et al: Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Cancer Group Trial 9401. J Clin Oncol 24:2428-2436, 2006
26. Harris L, Dressler L, Cowan D, et al: Comparison of HER-2 and topoisomerase IIa amplification with outcome after cyclophosphoamide, doxorubicin and 5 FU-based chemotherapy for Stage II breast cancer (CALGB 8541/150013). Proc Am Soc Clin Oncol 23:832, 2004 (abst)
27. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
28. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
29. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006 (abstr 52)
30. Hayes DF, Thor A, Dressler L, et al: HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol 24:5s, 2006 (abstr 510)
31. Petit T, Borel C, Ghnassia J-P, et al: Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clinical Cancer Res 7:1577-1581, 2001
32. Hudelist G, Kostler WJ, Attems J, et al: Her-2/neu-triggered intracellular tyrosine kinase activation: In vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 89:983-991, 2003
33. Hudelist G, Köstler WJ, Czerwenka K, et al: Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer 118:1126-1134, 2006